产后获得性血友病A患者母乳中艾美赛珠单抗的转移
本研究报道一名产后4个月发生获得性血友病A的哺乳期女性,在接受艾美赛珠单抗治疗期间采集血浆和母乳样本。结果显示母乳中可检测到艾美赛珠单抗,浓度最高达20 μg/mL,稳态血浆浓度为42 μg/mL;血浆中检出抗FVIII IgG和IgA,但母乳中未检出。提示需进一步研究婴儿暴露程度及临床相关性。
要点
- 产后获得性血友病A患者哺乳期使用艾美赛珠单抗时,药物可进入母乳。
- 母乳中艾美赛珠单抗浓度最高达20 μg/mL,同期稳态血浆浓度为42 μg/mL。
- 血浆中检出抗FVIII抗体,但母乳中未检出,提示抑制剂不通过母乳转移。
核心结论
- 产后获得性血友病A患者接受艾美赛珠单抗治疗期间,母乳中可检测到艾美赛珠单抗,但未检测到FVIII抑制剂。
研究设计与样本
- 病例研究,采集一名产后4个月发生获得性血友病A并接受艾美赛珠单抗治疗的哺乳期女性的血浆和母乳样本。
主要发现
- 母乳中艾美赛珠单抗在治疗开始后不久即可测得,浓度最高达20 μg/mL。
- 艾美赛珠单抗稳态血浆浓度为42 μg/mL。
- 血浆中检出抗FVIII IgG和IgA,母乳样本中未检出。
关键数值与推荐
- 艾美赛珠单抗母乳浓度最高20 μg/mL,稳态血浆浓度42 μg/mL。
临床怎么用
- 为接受艾美赛珠单抗治疗的哺乳期获得性血友病A女性提供咨询时,可告知药物可进入母乳但抑制剂未检出。
- 需进一步研究明确婴儿暴露程度及临床相关性,以支持共同决策。
局限性
- 单例病例报告,样本量有限。
- 婴儿暴露程度及临床相关性尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acquired hemophilia A (AHA) is a rare, potentially life-threatening autoimmune bleeding disorder caused by neutralizing autoantibodies against factor (F)VIII. The postpartum period is a recognized risk factor for AHA. Emicizumab is increasingly used for hemostatic prophylaxis in AHA, including in women who may wish to continue breastfeeding. However, data on transfer of emicizumab into breast milk are lacking. This limits evidence-based counseling and shared decision-making. OBJECTIVE: To assess whether emicizumab is detectable in the breast milk of a patient with postpartum AHA. METHODS: Plasma and breast milk samples were collected from a woman who developed AHA 4 months after delivery and was treated with emicizumab while breastfeeding. Samples were analyzed for emicizumab using a modified one-stage clot assay and for anti-FVIII immunoglobulin (Ig)G and IgA antibodies using immunoassays. RESULTS: Emicizumab was measurable in breast milk shortly after treatment initiation and reached concentrations of up to 20 μg/mL. The steady-state plasma concentration of emicizumab was 42 μg/mL. Anti-FVIII IgG and IgA were detected in plasma but not in breast milk samples. CONCLUSION: In this patient with postpartum AHA, emicizumab was detectable in breast milk, whereas FVIII inhibitors were not. These findings are relevant for counseling breastfeeding women receiving emicizumab. Further studies are needed to determine the extent and clinical relevance of infant exposure.
引用
- Krooss SA, Halling T, Varnholt D, et al. Transfer of emicizumab into breast milk in postpartum acquired hemophilia A. J Thromb Haemost. 2026. PMID: 42413825. doi:10.1016/j.jtha.2026.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。